bioAffinity Technologies Inc., a Delaware-based corporation, has entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC. This agreement allows for the sale of the company's common stock, valued at $0.007 per share, through an "at the market offering" program. Under this arrangement, shares may be sold directly on the Nasdaq Capital Market or other existing trading platforms at prevailing market prices. The company retains control over the sale parameters, including the number of shares, the timing, and any minimum price constraints. The agreement remains in effect until all shares are sold, but can be terminated by either party with a 10-day notice.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.